Efficacy of continuing anti-angiogenic agents in the second-line treatment for metastatic colon cancer depending on the KRAS mutation status: a meta-analysis

Authors: Fedyanin M.Y.¹, Tryakin A.A.¹, Tjulandin S.A.²
Affiliations:
1. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2. 24 Kashirskoe Shosse, Moscow 115478
Issue: Vol 8, No 2 (2018)
Pages: 38-45
Section: ORIGINAL REPORTS
Published: 12.07.2018
URL: https://onco-surgery.info/jour/article/view/249
DOI: https://doi.org/10.17650/2220-3478-2018-8-2-38-45
ID: 249

Cite item

Full Text

colon cancer, anti-angiogenic therapy, chemotherapy, randomized trials, meta-analysis, mutation in the KRAS gene

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Author for correspondence.
Email: fedianinmu@mail.ru
ORCID iD: 0000-0001-5615-7806
24 Kashirskoe Shosse, Moscow 115478 Russian Federation

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0003-2245-214X
24 Kashirskoe Shosse, Moscow 115478 Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

Russian Federation

Supplementary Files

Action

1. JATS XML